DE69311278D1 - Stabile pharmazeutische Zubereitung mit Fumagillolderivaten - Google Patents

Stabile pharmazeutische Zubereitung mit Fumagillolderivaten

Info

Publication number
DE69311278D1
DE69311278D1 DE69311278T DE69311278T DE69311278D1 DE 69311278 D1 DE69311278 D1 DE 69311278D1 DE 69311278 T DE69311278 T DE 69311278T DE 69311278 T DE69311278 T DE 69311278T DE 69311278 D1 DE69311278 D1 DE 69311278D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
stable pharmaceutical
fumagillol derivatives
fumagillol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69311278T
Other languages
English (en)
Other versions
DE69311278T2 (de
Inventor
Shigeo Yanai
Kazuhiro Saito
Hiroaki Okada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of DE69311278D1 publication Critical patent/DE69311278D1/de
Application granted granted Critical
Publication of DE69311278T2 publication Critical patent/DE69311278T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
DE69311278T 1992-12-16 1993-12-14 Stabile pharmazeutische Zubereitung mit Fumagillolderivaten Expired - Fee Related DE69311278T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33582892 1992-12-16

Publications (2)

Publication Number Publication Date
DE69311278D1 true DE69311278D1 (de) 1997-07-10
DE69311278T2 DE69311278T2 (de) 1997-10-30

Family

ID=18292862

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69311278T Expired - Fee Related DE69311278T2 (de) 1992-12-16 1993-12-14 Stabile pharmazeutische Zubereitung mit Fumagillolderivaten

Country Status (8)

Country Link
US (1) US5422363A (de)
EP (1) EP0602586B1 (de)
KR (1) KR940013499A (de)
CN (1) CN1093901A (de)
AT (1) ATE153854T1 (de)
CA (1) CA2111560A1 (de)
DE (1) DE69311278T2 (de)
PH (1) PH30120A (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5566069A (en) * 1994-03-07 1996-10-15 Monsanto Company Computer network for collecting and analyzing agronomic data
US5699244A (en) * 1994-03-07 1997-12-16 Monsanto Company Hand-held GUI PDA with GPS/DGPS receiver for collecting agronomic and GPS position data
EP0799616A1 (de) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Orale Zubereitung enthaltend ein Fumagillolderivat
US20010025046A1 (en) * 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
JP2002537358A (ja) 1999-02-26 2002-11-05 サノフィ−サンテラボ フマギリンを含有する安定な製剤
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
PL366216A1 (en) * 2000-11-01 2005-01-24 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7001603B2 (en) * 2001-02-28 2006-02-21 Color Access, Inc. Gelled two phase cosmetic compositions
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
AU2004312512A1 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
MX2010005857A (es) * 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
CN102123586A (zh) * 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
EP2486004B1 (de) 2009-10-09 2017-05-03 Zafgen, Inc. Sulfonverbindungen zur verwendung in der behandlung von adipositas
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
CA2817199C (en) 2010-11-09 2019-01-15 Zafgen, Inc. Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
MX2013005989A (es) 2010-11-29 2013-08-21 Zafgen Inc Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
BR112013023056A2 (pt) 2011-03-08 2018-10-09 Zafgen Inc derivados de oxaespiro [2,5] octano e análogos
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2705035B1 (de) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclische pyrazolsulfonamidverbindungen sowie verfahren und herstellung zu ihrer herstellung
EP2705030B1 (de) 2011-05-06 2016-07-27 Zafgen, Inc. Teilweise gesättigten trizyklishen verbindungen, deren herstellung und verwendung
EP2763671A2 (de) 2011-10-03 2014-08-13 Zafgen, Inc. Verfahren zur behandlung von altersbedingten erkrankungen
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
MX2015005734A (es) 2012-11-05 2016-02-10 Zafgen Inc Metodos de tratamiento de enfermedades hepaticas.
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CA3056614C (en) 2017-03-15 2023-09-26 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
BE1027390B1 (nl) 2019-06-21 2021-02-02 Nutrition Sciences Nv Mfca-samenstelling voor gebruik in de aquacultuur van schaaldieren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
KR0141692B1 (ko) * 1988-09-01 1998-06-01 우메모또 요시마사 맥관 형성 억제제
EP0682020A1 (de) * 1988-09-01 1995-11-15 Takeda Chemical Industries, Ltd. Fumagillolderivate verwendbar als Angiogeneseinhibitoren
ATE97410T1 (de) * 1989-03-06 1993-12-15 Takeda Chemical Industries Ltd 6-amino-6-desoxyfumagillole, ihre herstellung und ihre verwendung.
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance

Also Published As

Publication number Publication date
PH30120A (en) 1996-12-27
EP0602586A3 (de) 1994-08-31
CA2111560A1 (en) 1994-06-17
EP0602586B1 (de) 1997-06-04
CN1093901A (zh) 1994-10-26
EP0602586A2 (de) 1994-06-22
ATE153854T1 (de) 1997-06-15
US5422363A (en) 1995-06-06
KR940013499A (ko) 1994-07-15
DE69311278T2 (de) 1997-10-30

Similar Documents

Publication Publication Date Title
DE69311278D1 (de) Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
LV10907A (lv) Interferona polietilenglikola atvasinajums
FI863652A (fi) 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning.
DK0565549T3 (da) Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
NO911591L (no) Fremgangsmaate for fremstilling av sukrose-6-ester.
DE68901043D1 (de) Waessriges pharmazeutisches praeparat.
DE3875425D1 (de) Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen.
MX9205168A (es) Derivados de esteres azabiciclicos fusionados y procedimiento para su preparacion.
BR9709845A (pt) Preparação aquosa de insulina formulação farmacêutica parenteral e processo para aumentar a estabilidade química de uma preparação de insulina
ES2080549T3 (es) Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
NO913136L (no) Fremgangsmaate for fremstilling av et preparat for oeyedraaper
NO176082C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel
FI871345A0 (fi) Zwitterjoniska, bicykliska foereningar och deras salter, solvater, hydrater och estrar.
FI905748A0 (fi) Foerfarande foer framstaellning av 4-o -fosfater av dopamin och dopaminderivat.
DK585889D0 (da) Farmaceutisk praeparat
DK199789D0 (da) Anvendelse af et phenylquinolincarboxylsyrederivat eller et farmaceutisk egnet salt deraf til fremstilling af et topisk farmaceutisk praeparat til behandling af hud- og/eller slimepithelsygdomme
FI932769A (fi) Farmaceutisk komposition med foerbaettrad biotillgaenglighet och innehaollande probukol
DK627289D0 (da) Anvendelse af bicyclononanderivater
DE69001734D1 (de) Aeusserlich anzuwendende amusulosin enthaltende arzneizubereitung.
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
ATE120734T1 (de) Glyzerin-derivat und dessen pharmazeutische verwendung.
NO171912C (no) Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarboksylsyreestere
NO892495L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparat.
NO870950L (no) FremgangsmŸte for fremstilling av et stabilt injiserbart farmasŸytisk preparat.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee